Search

Purpose. To study suppressor and/or cytotoxic activity of the nuclear erythroid cells (NEC) against tumor cells of various origins. Material and Methods. C57Bl/6 mice and P815, L1210, B16 and L929 tumor cells were used. “Phenylhydrazine” NECs were obtained from mice with induced hemolytic anemia. “Erythropoietin” NECs were isolated from the “phenylhydrazine spleen” and further cultured in the presence of erythropoietin. Another source of NEC was neonatal mouse spleen, human and mouse fetal liver cells, and mouse bone marrow cells cultured with erythropoietin. The cytostatic effect of NEC or their supernatants was recorded by reducing proliferation of P815, L1210, B16, LLC, L929 lines. Results. The presence of pronounced direct antitumor activity was found in both NEC and their culturing products in relation to cells of various tumor lines. The suppressor effect was not specifc. Conclusion. We know about the signifcant numerical predominance of NEC during the embryo development over all other hematopoietic cells and their high suppressive potential. Therefore, it can be assumed that erythroblasts are involved in process of creating antitumor protection of a fetus during this period of life.

The purpose of the study was to identify and analyze the potential of immunotherapy aimed at enhancing the immune system’s ability to resist tumor development and (or) weakening the ability of the tumor to maintain its growth.Material and methods. A search for available literature sources published in Medline, Pubmed, etc. Databases was made. We found 215 publications regarding the study of the formation of antitumor mechanisms, of which 57 were included in this review.Results. The review was devoted to the analysis of the literature on tumor growth suppression by modulating inflammation, correcting the concentration of factors and enzymes, inhibiting the formation of immunosuppressive cells, enhancing antibody cytotoxicity, and stimulating cellular cytotoxicity. The feasibilities of antitumor vaccination were evaluated.Conclusion. Different immunotherapeutic effects were found can enhance the antitumor effect of each other. In the early stages of the disease, immunotherapy can eliminate tumor cells remaining in the body after surgical removal of the primary tumor. In the advanced stages of the disease, combined treatment, including traditional cytoreductive and immunotherapeutic treatment, should be aimed at inhibiting the development of the disease. The prognosis of the disease can be assessed on an inflammatory scale based on the determination of 3 blood parameters: the content of c-reactive protein, the level of lactate dehydrogenase, and the determination of the neutrophil-lymphocyte ratio.